Should I buy Johnson and Johnson stock today? (2024)

Should I buy Johnson and Johnson stock today?

The average price target represents 17.57% Increase from the current price of $152.39. Johnson & Johnson's analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

Is JNJ a good buy right now?

The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.

What will JNJ stock be worth in 5 years?

Johnson & Johnson stock price stood at $145.74

According to the latest long-term forecast, Johnson & Johnson price will hit $150 by the middle of 2024 and then $200 by the end of 2027. Johnson & Johnson will rise to $250 within the year of 2029 and $300 in 2033.

Is Johnson and Johnson a risky investment?

Key Points. Johnson & Johnson is one of the top healthcare companies in the world, with a market cap of nearly $400 billion. The company, however, faces an uncertain future because of its unsettled talc lawsuits. The litigation could threaten its dividend and long-term growth prospects.

What happens to my Johnson and Johnson stock when the company splits?

What does the J&J split mean for shareholders? If you currently own shares of Johnson & Johnson, when the company splits, you will own shares of both Johnson & Johnson – which will be the new pharmaceutical/medical device business – as well as shares of Kenvue, the new consumer health business.

Is Johnson and Johnson stock expected to go up?

Johnson & Johnson Stock Forecast

The 14 analysts with 12-month price forecasts for Johnson & Johnson stock have an average target of 166.21, with a low estimate of 40 and a high estimate of 215. The average target predicts an increase of 14.05% from the current stock price of 145.74.

Is JNJ a buy or sell?

Is Johnson & Johnson stock a Buy, Sell or Hold? Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 46 buy ratings, 32 hold ratings, and 1 sell ratings.

What is Johnson and Johnson forecast for 2024?

J&J now expects its adjusted earnings per share for 2024 to be in the range of $10.57 and $10.72, versus its prior estimate was $10.55 to $10.75. Johnson & Johnson's revenue of $21.4 billion in Q1 was up 2.3% y-o-y.

What is the future of Johnson and Johnson?

J&J expects to grow operational sales by 5%-7% through 2027. Notably, it anticipates a third of its sales to come from new products in 2027. The company set 2024 sales growth forecasts for between 5%-6%.

What is the long term outlook for JNJ?

In December, the company announced its long-term guidance, which projected an annual growth rate between 5% and 7% from 2025 through to 2030.

Why should I buy JNJ stock?

Johnson & Johnson's JNJ biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. J&J has 25 platforms with more than $1 billion in annual sales.

Will Johnson and Johnson stock recover?

We estimate Johnson & Johnson's Valuation to be $180 per share, reflecting over 10% upside from its current levels of $158. Our forecast is based on a 17x P/E multiple for JNJ and expected earnings of $10.70 on a per-share and adjusted basis for the full year 2024.

Is JNJ a good long term stock?

Johnson & Johnson (NYSE:JNJ) is a prominent member of the Dividend Kings, having raised its dividends for 61 consecutive years. Due to its long history of dividend payments, JNJ is among Wall Street's favorite long-term stocks.

Who are the largest shareholders of Johnson and Johnson?

Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VFINX - Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, Morgan Stanley, State Farm Mutual Automobile Insurance Co, Spdr S&p 500 Etf Trust, and ...

Is JNJ going to split into two companies?

Johnson & Johnson is splitting into two companies, separating the division that sells Band-Aids and Listerine, from its medical device and prescription drug business. Johnson & Johnson is peeling off a consumer health business that helped it become the world's biggest health care products maker.

Do you lose value in your stock if a company splits their stock?

A stock split lowers its stock price but doesn't weaken its value to current shareholders. It increases the number of shares and might entice would-be buyers to make a purchase. The total value of the stock shares remains unchanged because you still own the same value of shares, even if the number of shares increases.

What will Johnson and Johnson stock price be in 2025?

Johnson & Johnson stock prediction for 1 year from now: $ 121.86 (-15.72%) Johnson & Johnson stock forecast for 2025: $ 152.69 (5.70%)

What is the JNJ stock price forecast for 12 months?

Based on analysts offering 12 month price targets for JNJ in the last 3 months. The average price target is $174.8 with a high estimate of $215 and a low estimate of $155.

Is Coca Cola a buy or sell?

Is Coca-Cola stock a Buy, Sell or Hold? Coca-Cola stock has received a consensus rating of buy. The average rating score is A1 and is based on 37 buy ratings, 9 hold ratings, and 0 sell ratings.

Can I invest in Johnson and Johnson?

Johnson & Johnson does not have a direct purchase program available to the general public. However, existing shareowners may make additional purchases of stock without fees or commissions through the Johnson & Johnson Dividend Reinvestment Program (DRIP).

What is the book value of Johnson and Johnson stock?

Johnson & Johnson (Johnson & Johnson) Book Value per Share. Johnson & Johnson's book value per share for the quarter that ended in Dec. 2023 was $28.57.

Is Apple a good stock to buy right now?

The financial health and growth prospects of AAPL, demonstrate its potential to underperform the market. It currently has a Growth Score of A. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.

What are the top selling drugs of Johnson and Johnson?

Pharmaceutical Sales - $45.6 billion. Top revenue-producing drugs include: Stelara, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, Opsumit.

Is Johnson and Johnson profitable?

Johnson & Johnson annual gross profit for 2022 was $55.394B, a 0.1% increase from 2021. Johnson & Johnson annual gross profit for 2021 was $55.338B, a 2.18% increase from 2020.

What are the challenges faced by Johnson and Johnson?

The biggest risk facing Johnson & Johnson (JNJ 0.22%) today is its exposure to talc-related lawsuits. The company has already spent billions on payouts and legal costs to address lawsuits from people who allege they developed cancer from the use of its baby powder products contaminated with asbestos.

You might also like
Popular posts
Latest Posts
Article information

Author: Gregorio Kreiger

Last Updated: 15/05/2024

Views: 5618

Rating: 4.7 / 5 (77 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Gregorio Kreiger

Birthday: 1994-12-18

Address: 89212 Tracey Ramp, Sunside, MT 08453-0951

Phone: +9014805370218

Job: Customer Designer

Hobby: Mountain biking, Orienteering, Hiking, Sewing, Backpacking, Mushroom hunting, Backpacking

Introduction: My name is Gregorio Kreiger, I am a tender, brainy, enthusiastic, combative, agreeable, gentle, gentle person who loves writing and wants to share my knowledge and understanding with you.